UP!
|
Type
|
Public |
|---|---|
| Traded as | NASDAQ: AEZS TSX: AEZ |
| Industry | Biotechnology |
| Headquarters | Quebec, Canada |
|
Key people
|
|
| Website | www |
Æterna Zentaris Inc. is a Quebec, Canada-based biopharmaceutical drug development company focused in oncology and endocrine therapy, currently investigating treatments for various unmet medical needs. The Company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. It has over 80 employees in Canada, United States and Germany. The company is based in Canada, the development and research site is based in Germany. The company has 3 lead projects: an ongoing Phase 3 trial in multiple myeloma (a form of blood cancer) conducted under a Special Protocol Assessment (SPA): a Phase 3 trial in endometrial cancer with AEZS-108 expected to be initiated in 1Q 2013, and a New Drug Application (NDA) expected to be filed in 1Q 2013 for the approval of AEZS-130 as potentially the first oral diagnostic test for adult growth hormone deficiency (AGHD).
Perifosine: Fast track designation and orphan drug status granted by the FDA. Orphan Medicinal Product designation and positive Scientific Advice granted by the EMA .
AEZS-108: Orphan drug and Orphan medicinal product designations granted by the FDA and EMA respectively, for the treatment of ovarian cancer.
AEZS-130: Orphan drug designation granted by the FDA for use as a diagnostic test for AGHD.
As of December 2013, the company's Chief Commercial Officer is Jude Dinges.
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q3 2020 | 2022-11-02 | Future report Set alerts | |
| Q2 2020 | 2022-08-03 | -0.87 | -0.87 |
| Q1 2020 | 2022-05-09 | -0.02 | -0.02 |
| Q4 2019 | 2022-03-27 | -0.02 | -0.02 |
| Q3 2019 | 2021-11-04 | 0.00 | 0.00 |
| Q2 2019 | 2021-08-04 | 0.00 | 0.00 |
| Q1 2019 | 2019-05-07 | -0.30 | -0.30 |
| Q4 2018 | 2019-03-26 | -0.31 | -0.31 |
| Q3 2018 | 2018-11-06 | -0.15 | -0.15 |
| 2016-07-10 | Reiterated Rating | HC Wainwright | Buy | $12.00 |
| 2016-07-05 | Reiterated Rating | Maxim Group | Buy | $11.00 |
| 2016-06-15 | Reiterated Rating | Maxim Group | Buy | $11.00 |
| 2016-05-10 | Reiterated Rating | Maxim Group | Buy | $11.00 |
| 2016-05-02 | Reiterated Rating | Maxim Group | Buy | $11.00 |
| 2016-04-04 | Reiterated Rating | Canaccord Genuity | Buy | $13.00 to $9.00 |
| 2016-03-03 | Reiterated Rating | Maxim Group | Buy | $11.00 |
| 2016-01-20 | Reiterated Rating | Maxim Group | Buy | $11.00 |
| 2015-12-02 | Reiterated Rating | Canaccord Genuity | Buy | |
| 2015-12-02 | Boost Price Target | HC Wainwright | Buy | $11.00 to $12.00 |
| 2015-11-25 | Reiterated Rating | Canaccord Genuity | Buy | $0.10 to $13.00 |
| 2015-11-09 | Upgrade | Canaccord Genuity | Hold to Buy | |
| 2015-11-06 | Reiterated Rating | Maxim Group | Buy | $2.00 |
| 2015-10-13 | Reiterated Rating | Maxim Group | Buy | $2.00 |
| 2015-09-28 | Reiterated Rating | Maxim Group | Buy | $2.00 |
| 2015-08-18 | Lower Price Target | HC Wainwright | Buy | $1.25 to $1.00 |
| 2015-08-17 | Initiated Coverage | Canaccord Genuity | Hold | |
| 2015-08-16 | Reiterated Rating | Maxim Group | Buy | |
| 2015-07-28 | Reiterated Rating | Maxim Group | Buy | $2.00 |
| 2015-07-02 | Reiterated Rating | Maxim Group | Buy | |
| 2015-06-17 | Reiterated Rating | Maxim Group | Buy | $2.00 |
| 2015-05-23 | Reiterated Rating | HC Wainwright | Buy | $1.25 |
| 2015-05-12 | Reiterated Rating | Canaccord Genuity | Hold | $0.70 |
| 2015-04-14 | Upgrade | HC Wainwright | Neutral to Buy | $1.25 |
| 2015-03-24 | Reiterated Rating | HC Wainwright | Hold | |
| 2014-12-29 | Set Price Target | Maxim Group | Buy | $2.00 |
| 2014-11-10 | Downgrade | Maxim Group | Sell | |
| 2014-11-06 | Downgrade | H.C. Wainwright | Buy to Neutral | |
| 2014-11-06 | Downgrade | HC Wainwright | Buy to Neutral | |
| 2014-07-17 | Initiated | H.C. Wainwright | Buy | $3 |
| 2014-07-17 | Initiated Coverage | HC Wainwright | Buy | $3.00 |
| 2013-01-03 | Upgrade | MLV & Co | Hold to Buy | $5.50 |
| 2012-10-09 | Initiated | Maxim Group | Buy | $9 |
| 2012-04-02 | Downgrade | MLV & Co | Buy to Hold | |
| 2011-06-07 | Initiated | Oppenheimer | Outperform | $5.50 |
| 2011-04-27 | Reiterated | Canaccord Genuity | Speculative Buy | $2.75 to $4 |
| 2010-11-29 | Initiated | MLV Capital | Buy | $5.50 |
| 2009-02-05 | Upgrade | RBC Capital Mkts | Sector Perform to Outperform | |
| 2008-06-03 | Reiterated | Canaccord Adams | Buy | $3.20 to $2.65 |
| 2008-04-14 | Reiterated | Canaccord Adams | Buy | $4.50 to $3.20 |
| 2007-10-03 | Reiterated | Rodman & Renshaw | Mkt Outperform | $8 to $6 |
| 2007-08-15 | Upgrade | RBC Capital Mkts | Sector Perform to Outperform | |
| 2007-05-15 | Initiated | Oppenheimer | Buy | $7 |
| 2007-05-09 | Reiterated | Rodman & Renshaw | Mkt Outperform | $10 to $8 |
| 2016-07-10 | Reiterated Rating | HC Wainwright | Buy | $12.00 |
| 2016-07-05 | Reiterated Rating | Maxim Group | Buy | $11.00 |
| 2016-06-15 | Reiterated Rating | Maxim Group | Buy | $11.00 |
| 2016-05-10 | Reiterated Rating | Maxim Group | Buy | $11.00 |
| 2016-05-02 | Reiterated Rating | Maxim Group | Buy | $11.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In AEZS 12 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| KCG Holdings, Inc. | 18577 |
| Nine Chapters Capital Management LLC | 18500 |
| MORGAN STANLEY | 13850 |
| GROUP ONE TRADING, L.P. | 8883 |
| ROYAL BANK OF CANADA | 488 |
| Tower Research Capital LLC (TRC) | 478 |
| BANK OF AMERICA CORP /DE/ | 200 |
| WELLS FARGO & CO/MN | 200 |
| NEXT Financial Group, Inc | 114 |
| Focused Wealth Management, Inc | 60 |
| MetLife Securities, Inc | 12 |
| LADENBURG THALMANN FINANCIAL SERVICES INC | 3 |
UM